1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Global Inhaled Nitric Oxide Market By Application, By Region, Industry Analysis and Forecast, 2020 - 2026

Global Inhaled Nitric Oxide Market By Application, By Region, Industry Analysis and Forecast, 2020 - 2026

  • February 2021
  • 123 pages
  • ID: 6046677
  • Format: PDF
  • KBV Research
Up to $907 off Until May 20th 2021

Summary

Table of Contents

Search Inside

The Global Inhaled Nitric Oxide Market size is expected to reach $915.7 Million by 2026, rising at a market growth of 7% CAGR during the forecast period. Nitric oxide is a molecule of gas that causes a sense of relaxation in smooth muscle cells in the vasculature. It is because Nitric Oxide reacts with oxyhemoglobin. The gas is quickly collected by oxyhemoglobin in red blood cells and the vasodilating effects caused by inhaled nitric oxide are restricted to oxygenated areas of the lungs. Thus, this distinct ability of Nitric oxide to cause pulmonary vasodilatation in the oxygenated regions of the lung helps in enhancing oxygenation of the blood and reduces intrapulmonary right to left shunting. Hence, the inhaled nitric oxide is utilized to cure various cardiopulmonary conditions, like pulmonary hypertension in adults and children. Although, the usage of inhaled nitric oxide is restricted due to logistical and financial reasons.

The rising prevalence of diseases in infants like a neonatal hypoxic respiratory failure (HRF) and persistent pulmonary hypertension is among the key driving factors of the market. Moreover, the growing number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) also propel the market growth. Apart from this, the huge cost involved in the treatment & the stringent government policies on different applications of the gas are restricting the growth of Inhaled Nitric Oxide market. However, the constant R&D activities for discovering various new applications in the healthcare sector are estimated to offer profitable opportunities for expanding the global inhaled nitric oxide market during the forecast period.

The declaration of WHO about the Covid-19 outbreak as a public health emergency has affected every country around the globe. During the pandemic, nitric oxide got under several experiments to test whether it can help in treating Covid-19 affected people, due to its antiviral properties and enhanced oxygenation. Inhaled Nitric Oxide is useful in safeguarding the frontline healthcare workers from this pandemic.

Application Outlook

Based on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications. Neonatal respiratory treatment segment procured the substantial revenue share and is estimated to exhibit high growth rate during the forecast period. This is due a surge in the occurrences of diseases in the newborn like persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). The chronic obstructive pulmonary disease segment would display promising growth rate during the forecast period.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the global inhaled nitric oxide market in 2019. The high growth of the regional market is due to the large consumer base & rising funding in R&D by the leading players. Major determinants such as surge in rates of chronic diseases in the newborn like persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF) are expected to support the market growth.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.

Strategies deployed in Inhaled Nitric Oxide Market

Dec-2020: Beyond Air introduced a pilot clinical trial analyzing its investigational therapy LungFit GO. It is an inhaled nitric oxide, which can be self-administrated at home, in adults with or without cystic fibrosis (CF) those who have chronic, treatment-resistant lung infections caused by non-tuberculosis mycobacteria (NTM).

Nov-2020: Mallinckrodt announced the beginning of a retrospective chart review study, under the title "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to accumulate real-world data on the usage of INOmax (nitric oxide) gas, for inhalation therapy in patients with respiratory complications related to the novel coronavirus SARS-CoV-2 (COVID-19).

Nov-2020: Beyond Air submitted its premarket approval (PMA) application for its LungFit PH to the U.S. Food and Drug Administration (FDA). LungFit PH helps in curing persistent pulmonary hypertension of the newborn (PPHN). FDA guidelines permitted for a 180-day review period for a PMA. LungFit PH produces nitric oxide from ambient air and transmits it to a ventilator making it a safer and more convenient environment for patients and medical staff.

Oct-2020: Beyond Air announced the beginning of a clinical study of the LungFit system. This system is used for assessment of the safety and efficacy of high concentration inhaled NO given at particular intervals to the hospitalized adults with acute viral pneumonia, including SARS-CoV-2.

May-2020: Mallinckrodt joined hands with Massachusetts General Hospital. In this collaboration, the companies aimed to analyze the potential advantages of inhaled nitric oxide as a treatment for pulmonary complications in COVID-19 patients. The collaboration also evaluate the benefits of INOmax (nitric oxide) gas in mechanically ventilated patients who have serious Acute Respiratory Syndrome caused by COVID-19.

Apr-2020: Mallinckrodt and Novoteris got approval by Health Canada for initiating a pilot study of an inhaled formulation of nitric oxide (NO) as a possible treatment for coronavirus. This study was carried out at Vancouver Coastal Health Authority facilities. It has tested a high-concentration form of NO called Thiolanox in development by the companies, delivered by utilizing a specialized Novoteris delivery device.

Apr-2020: Beyond Air got a clean chit by the U.S. Food and Drug Administration (FDA) for initiating a clinical study in the U.S. using the LungFit TM system to cure COVID-19 patients. Applications for funding were incomplete with the Biomedical Advance Research and Development Authority (BARDA), a division of Health and Human Services (HHS).

Mar-2020: Beyond Air received an approval from Health Canada to use LungFit system for study in hospitalized patients infected with COVID-19 caused by the serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Dec-2019: VERO Biotech received an approval of GENOSYL (nitric oxide) gas, for inhalation by the US Food and Drug Administration (FDA). GENOSYL is contraindicated in the process of treating the neonates dependent on right-to-left shunting of blood.

Jun-2017: Novoteris announced that the US Food and Drug Administration and the Therapeutic Products Directorate of Health Canada have given them a clean chit on its Phase 2 clinical trial application. The company has further initiated recruiting subjects into its Phase 2 trial that used inhaled nitric oxide for the treatment of Cystic Fibrosis (CF).

Feb-2017: Nu-Med Plus signed a stock agreement with Smith Corporate Services, a professional project management and contact center management consulting firm. The agreement enabled company to continue to move forward by redefining the INO arena and move further on the path to fill for regulatory approval of their products which included their proprietary conversion technology.

Scope of the Study

Market Segments covered in the Report:

By Application

• Neonatal Respiratory Treatment

• Chronic Obstructive Pulmonary Disease (COPD)

• Acute Respiratory Distress Syndrome (ARDS)

• Other Applications

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Australia

o Rest of Asia Pacific

• LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Getinge AB

• Merck Group

• Halma PLC

• Linde PLC (Praxair, Inc.)

• Air Liquide S.A.

• Beyond Air, Inc.

• Mallinckrodt PLC (International Minerals and Chemical Corporation)

• VERO Biotech LLC

• Nu-Med Plus, Inc.

• Novoteris, LLC

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
15% Off

$3600

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on